Chronic Hepatitis, Hepatocellular Carcinoma, Liver cirrhosis
Conditions
Interventions
None listed
Sponsors
Nagoya University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adult patients aged 18 and over undergoing treatment for liver diseases including HCC at our institution Patients with an ECOG Performance Status (PS) of 0-2 Consent obtained from the patient in writing
Exclusion criteria
Exclusion criteria: Patients with galactosemia Patients who have experienced allergies to foods containing sugar alcohols Patients with poorly controlled diabetes Patients who wish to be excluded from the study Patients who are pregnant, nursing, possibly pregnant or wish to become pregnant, or wishing to raise children Other patients whom the physician has judged to be inappropriate for safely conducting this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In patients with hepatocellular carcinoma undergoing chemotherapy, identifying differences in gut microbiota and intestinal permeability between the groups with favorable treatment outcomes (where the response during administration is evaluated as stable disease (SD) or better, according to m-RECIST and RECIST criteria) and the groups with unfavorable outcomes (where the response during administration is evaluated as progressive disease (PD)). | — |
Secondary
| Measure | Time frame |
|---|---|
| Identification of gut microbiota and differences in intestinal permeability associated with adverse events during the treatment period. | — |
Countries
Japan
Contacts
Public ContactKenta Yamamoto
Nagoya University Hospital Department of Gastroenterology and Hepatology
Outcome results
None listed